Mankind Pharma

Mankind Pharma ROE

The Return on Equity (ROE) of Mankind Pharma (MANKIND.NS) as of Oct 20, 2026 is 11.74 %. In the previous year, Return on Equity (ROE) was 13.89 % — a change of -15.52% (lower).

ROE

11.74 %

YoY

-15.52%

Last updated:

In 2026, Mankind Pharma's return on equity (ROE) was 11.74 %, a -15.52% increase from the 13.89 % ROE in the previous year.

The Mankind Pharma ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2019
20.49 INR
Jan 1, 2020
29.56 INR
Jan 1, 2021
26.80 INR
Jan 1, 2022
23.29 INR
Jan 1, 2023
17.24 INR
Jan 1, 2024
20.43 INR
Jan 1, 2025
13.89 INR
Jan 1, 2026
11.74 INR
The Mankind Pharma ROE history
YEARROEYoY
11.74 %-15.52%
13.89 %-32.01%
20.43 %+18.50%
17.24 %-25.97%
23.29 %-13.10%
26.80 %-9.36%
29.56 %+44.27%
20.49 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Mankind Pharma Stock analysis

What does Mankind Pharma do? Mankind Pharma Ltd., headquartered in New Delhi, India, operates in the Health Care sector, specializing in pharmaceutical formulations. The company develops, manufactures, and markets a wide range of products across acute and chronic therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, and dermatology treatments. With 18,468 employees, it serves diverse markets through its extensive portfolio of brands such as Nurokind, Telmikind, and Manforce (Rx). Listed on 9 May 2023, the firm focuses on both prescription and consumer healthcare solutions. Mankind Pharma is one of the most popular companies on Eulerpool.

ROE Details

Decoding Mankind Pharma's Return on Equity (ROE)

Mankind Pharma's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Mankind Pharma's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Mankind Pharma's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Mankind Pharma’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Mankind Pharma stock

Return on Equity (ROE) of Mankind Pharma is 11.74 % in 2026.

Return on Equity (ROE) of Mankind Pharma changed from 13.89 % to 11.74 %, representing a -15.52% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Mankind Pharma since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Mankind Pharma with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Mankind Pharma

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Mankind Pharma